Review



biotinylated recombinant human fcγri (cd64)  (ACROBiosystems)


Bioz Verified Symbol ACROBiosystems is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ACROBiosystems biotinylated recombinant human fcγri (cd64)
    TSLP binding and epitope competition studies for TAVO101 and tezepelumab. (A) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their binding to immobilized human TSLP. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their inhibition on the binding of human TSLP to its receptor complex expressed on the surface of HEK293T cells transfected with IL7Rα and TSLPR by flow cytometry. Mean fluorescence intensities (MFI) representing TSLP binding were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3). (C) . Epitope competition binding assays for TAVO101 and tezepelumab by gator Bio-layer Interferometry. After loading the biosensor with <t>biotinylated</t> TSLP during the first binding phase, either TAVO101 (left panel) or tezepelumab (right panel) was added until the binding to the TSLP on the biosensor was saturated during the second phase. In the third binding phase, either tezepelumab or TAVO101 was then added to monitor kinetic binding to the TSLP on the biosensor. Shifts in interference reflecting the binding of test antibodies to TSLP were plotted against time (in second) during the three phases of binding. In each assay, triplicate binding profiles for the competition antibody addition and a single binding profile for the same antibody addition during the third binding phase were shown.
    Biotinylated Recombinant Human Fcγri (Cd64), supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+recombinant+human+fc%CE%B3ri+(cd64)/human+fc+gamma+receptor+i+cd64/pmc11670205-100-3-11
    Average 90 stars, based on 1 article reviews
    biotinylated recombinant human fcγri (cd64) - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases"

    Article Title: A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2024.1442588

    TSLP binding and epitope competition studies for TAVO101 and tezepelumab. (A) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their binding to immobilized human TSLP. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their inhibition on the binding of human TSLP to its receptor complex expressed on the surface of HEK293T cells transfected with IL7Rα and TSLPR by flow cytometry. Mean fluorescence intensities (MFI) representing TSLP binding were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3). (C) . Epitope competition binding assays for TAVO101 and tezepelumab by gator Bio-layer Interferometry. After loading the biosensor with biotinylated TSLP during the first binding phase, either TAVO101 (left panel) or tezepelumab (right panel) was added until the binding to the TSLP on the biosensor was saturated during the second phase. In the third binding phase, either tezepelumab or TAVO101 was then added to monitor kinetic binding to the TSLP on the biosensor. Shifts in interference reflecting the binding of test antibodies to TSLP were plotted against time (in second) during the three phases of binding. In each assay, triplicate binding profiles for the competition antibody addition and a single binding profile for the same antibody addition during the third binding phase were shown.
    Figure Legend Snippet: TSLP binding and epitope competition studies for TAVO101 and tezepelumab. (A) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their binding to immobilized human TSLP. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their inhibition on the binding of human TSLP to its receptor complex expressed on the surface of HEK293T cells transfected with IL7Rα and TSLPR by flow cytometry. Mean fluorescence intensities (MFI) representing TSLP binding were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3). (C) . Epitope competition binding assays for TAVO101 and tezepelumab by gator Bio-layer Interferometry. After loading the biosensor with biotinylated TSLP during the first binding phase, either TAVO101 (left panel) or tezepelumab (right panel) was added until the binding to the TSLP on the biosensor was saturated during the second phase. In the third binding phase, either tezepelumab or TAVO101 was then added to monitor kinetic binding to the TSLP on the biosensor. Shifts in interference reflecting the binding of test antibodies to TSLP were plotted against time (in second) during the three phases of binding. In each assay, triplicate binding profiles for the competition antibody addition and a single binding profile for the same antibody addition during the third binding phase were shown.

    Techniques Used: Binding Assay, Inhibition, Transfection, Flow Cytometry, Fluorescence

    Fc engineering of TAVO101 for extended half-life and reduced Fcγ receptor binding. (A) . Binding to mouse FcRn by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS and TAVO101_IgG1-FEA were assessed for their binding to immobilized mouse FcRn at pH 6.0 in ELISA assays. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Pharmacokinetic profile of an Fc engineered TAVO101. TAVO101_IgG1-AALS antibody was administered as a single 4 mg/kg intravenous dose into a cynomolgus monkey. The antibody concentrations in plasma at time points up to day 35 post-dose were quantitated and plotted against the testing days. The calculated pharmacokinetic parameters were shown. (C) . Binding to human Fcγ receptors and C1q complement protein by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS antibody and a human IgG1 control antibody were assessed for their binding to FcγRI (CD64), FcγRIIIA (CD16a), and C1q. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3).
    Figure Legend Snippet: Fc engineering of TAVO101 for extended half-life and reduced Fcγ receptor binding. (A) . Binding to mouse FcRn by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS and TAVO101_IgG1-FEA were assessed for their binding to immobilized mouse FcRn at pH 6.0 in ELISA assays. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Pharmacokinetic profile of an Fc engineered TAVO101. TAVO101_IgG1-AALS antibody was administered as a single 4 mg/kg intravenous dose into a cynomolgus monkey. The antibody concentrations in plasma at time points up to day 35 post-dose were quantitated and plotted against the testing days. The calculated pharmacokinetic parameters were shown. (C) . Binding to human Fcγ receptors and C1q complement protein by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS antibody and a human IgG1 control antibody were assessed for their binding to FcγRI (CD64), FcγRIIIA (CD16a), and C1q. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3).

    Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Control

    Related Articles

    Recombinant:

    Article Title: A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases
    Article Snippet: .. 100 nM of biotinylated recombinant human FcγRI (CD64) or FcγRIIIA (CD16a) (AcroBiosystems, Newark, DE) were coated on 96-well plate pre-coated with streptavidin (Sigma, St. Louis, MO). ..



    Similar Products

    biotinylated recombinant human fcγri (cd64)  (ACROBiosystems)
    90
    ACROBiosystems biotinylated recombinant human fcγri (cd64)
    TSLP binding and epitope competition studies for TAVO101 and tezepelumab. (A) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their binding to immobilized human TSLP. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their inhibition on the binding of human TSLP to its receptor complex expressed on the surface of HEK293T cells transfected with IL7Rα and TSLPR by flow cytometry. Mean fluorescence intensities (MFI) representing TSLP binding were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3). (C) . Epitope competition binding assays for TAVO101 and tezepelumab by gator Bio-layer Interferometry. After loading the biosensor with <t>biotinylated</t> TSLP during the first binding phase, either TAVO101 (left panel) or tezepelumab (right panel) was added until the binding to the TSLP on the biosensor was saturated during the second phase. In the third binding phase, either tezepelumab or TAVO101 was then added to monitor kinetic binding to the TSLP on the biosensor. Shifts in interference reflecting the binding of test antibodies to TSLP were plotted against time (in second) during the three phases of binding. In each assay, triplicate binding profiles for the competition antibody addition and a single binding profile for the same antibody addition during the third binding phase were shown.
    Biotinylated Recombinant Human Fcγri (Cd64), supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+recombinant+human+fc%CE%B3ri+(cd64)/human+fc+gamma+receptor+i+cd64/pmc11670205-100-3-11
    Average 90 stars, based on 1 article reviews
    biotinylated recombinant human fcγri (cd64) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    biotinylated anti fcγri  (R&D Systems Hematology)
    94
    R&D Systems Hematology biotinylated anti fcγri
    TSLP binding and epitope competition studies for TAVO101 and tezepelumab. (A) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their binding to immobilized human TSLP. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their inhibition on the binding of human TSLP to its receptor complex expressed on the surface of HEK293T cells transfected with IL7Rα and TSLPR by flow cytometry. Mean fluorescence intensities (MFI) representing TSLP binding were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3). (C) . Epitope competition binding assays for TAVO101 and tezepelumab by gator Bio-layer Interferometry. After loading the biosensor with <t>biotinylated</t> TSLP during the first binding phase, either TAVO101 (left panel) or tezepelumab (right panel) was added until the binding to the TSLP on the biosensor was saturated during the second phase. In the third binding phase, either tezepelumab or TAVO101 was then added to monitor kinetic binding to the TSLP on the biosensor. Shifts in interference reflecting the binding of test antibodies to TSLP were plotted against time (in second) during the three phases of binding. In each assay, triplicate binding profiles for the competition antibody addition and a single binding profile for the same antibody addition during the third binding phase were shown.
    Biotinylated Anti Fcγri, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+recombinant+human+fc%CE%B3ri+(cd64)/Recombinant+Human+Fc+gamma+RI%2FCD64+Protein%2C+CF/us08586048-457-4-6
    Average 94 stars, based on 1 article reviews
    biotinylated anti fcγri - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    TSLP binding and epitope competition studies for TAVO101 and tezepelumab. (A) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their binding to immobilized human TSLP. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their inhibition on the binding of human TSLP to its receptor complex expressed on the surface of HEK293T cells transfected with IL7Rα and TSLPR by flow cytometry. Mean fluorescence intensities (MFI) representing TSLP binding were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3). (C) . Epitope competition binding assays for TAVO101 and tezepelumab by gator Bio-layer Interferometry. After loading the biosensor with biotinylated TSLP during the first binding phase, either TAVO101 (left panel) or tezepelumab (right panel) was added until the binding to the TSLP on the biosensor was saturated during the second phase. In the third binding phase, either tezepelumab or TAVO101 was then added to monitor kinetic binding to the TSLP on the biosensor. Shifts in interference reflecting the binding of test antibodies to TSLP were plotted against time (in second) during the three phases of binding. In each assay, triplicate binding profiles for the competition antibody addition and a single binding profile for the same antibody addition during the third binding phase were shown.

    Journal: Frontiers in Immunology

    Article Title: A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases

    doi: 10.3389/fimmu.2024.1442588

    Figure Lengend Snippet: TSLP binding and epitope competition studies for TAVO101 and tezepelumab. (A) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their binding to immobilized human TSLP. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Increasing concentrations of TAVO101 and tezepelumab were assessed for their inhibition on the binding of human TSLP to its receptor complex expressed on the surface of HEK293T cells transfected with IL7Rα and TSLPR by flow cytometry. Mean fluorescence intensities (MFI) representing TSLP binding were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3). (C) . Epitope competition binding assays for TAVO101 and tezepelumab by gator Bio-layer Interferometry. After loading the biosensor with biotinylated TSLP during the first binding phase, either TAVO101 (left panel) or tezepelumab (right panel) was added until the binding to the TSLP on the biosensor was saturated during the second phase. In the third binding phase, either tezepelumab or TAVO101 was then added to monitor kinetic binding to the TSLP on the biosensor. Shifts in interference reflecting the binding of test antibodies to TSLP were plotted against time (in second) during the three phases of binding. In each assay, triplicate binding profiles for the competition antibody addition and a single binding profile for the same antibody addition during the third binding phase were shown.

    Article Snippet: 100 nM of biotinylated recombinant human FcγRI (CD64) or FcγRIIIA (CD16a) (AcroBiosystems, Newark, DE) were coated on 96-well plate pre-coated with streptavidin (Sigma, St. Louis, MO).

    Techniques: Binding Assay, Inhibition, Transfection, Flow Cytometry, Fluorescence

    Fc engineering of TAVO101 for extended half-life and reduced Fcγ receptor binding. (A) . Binding to mouse FcRn by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS and TAVO101_IgG1-FEA were assessed for their binding to immobilized mouse FcRn at pH 6.0 in ELISA assays. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Pharmacokinetic profile of an Fc engineered TAVO101. TAVO101_IgG1-AALS antibody was administered as a single 4 mg/kg intravenous dose into a cynomolgus monkey. The antibody concentrations in plasma at time points up to day 35 post-dose were quantitated and plotted against the testing days. The calculated pharmacokinetic parameters were shown. (C) . Binding to human Fcγ receptors and C1q complement protein by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS antibody and a human IgG1 control antibody were assessed for their binding to FcγRI (CD64), FcγRIIIA (CD16a), and C1q. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3).

    Journal: Frontiers in Immunology

    Article Title: A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases

    doi: 10.3389/fimmu.2024.1442588

    Figure Lengend Snippet: Fc engineering of TAVO101 for extended half-life and reduced Fcγ receptor binding. (A) . Binding to mouse FcRn by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS and TAVO101_IgG1-FEA were assessed for their binding to immobilized mouse FcRn at pH 6.0 in ELISA assays. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=2). (B) . Pharmacokinetic profile of an Fc engineered TAVO101. TAVO101_IgG1-AALS antibody was administered as a single 4 mg/kg intravenous dose into a cynomolgus monkey. The antibody concentrations in plasma at time points up to day 35 post-dose were quantitated and plotted against the testing days. The calculated pharmacokinetic parameters were shown. (C) . Binding to human Fcγ receptors and C1q complement protein by Fc engineered TAVO101. Increasing concentrations of TAVO101_IgG1-AALS antibody and a human IgG1 control antibody were assessed for their binding to FcγRI (CD64), FcγRIIIA (CD16a), and C1q. OD at 450 nm were plotted against the concentrations of test antibodies (Data expressed as mean ± SEM, n=3).

    Article Snippet: 100 nM of biotinylated recombinant human FcγRI (CD64) or FcγRIIIA (CD16a) (AcroBiosystems, Newark, DE) were coated on 96-well plate pre-coated with streptavidin (Sigma, St. Louis, MO).

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Control